157 related articles for article (PubMed ID: 23458062)
1. Phosphorylated Smad2 and Smad3 signaling: Shifting between tumor suppression and fibro-carcinogenesis in chronic hepatitis C.
Yamaguchi T; Matsuzaki K; Inokuchi R; Kawamura R; Yoshida K; Murata M; Fujisawa J; Fukushima N; Sata M; Kage M; Nakashima O; Tamori A; Kawada N; Tsuneyama K; Dooley S; Seki T; Okazaki K
Hepatol Res; 2013 Dec; 43(12):1327-42. PubMed ID: 23458062
[TBL] [Abstract][Full Text] [Related]
2. Reversible Human TGF-β Signal Shifting between Tumor Suppression and Fibro-Carcinogenesis: Implications of Smad Phospho-Isoforms for Hepatic Epithelial-Mesenchymal Transitions.
Yoshida K; Murata M; Yamaguchi T; Matsuzaki K; Okazaki K
J Clin Med; 2016 Jan; 5(1):. PubMed ID: 26771649
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B.
Murata M; Matsuzaki K; Yoshida K; Sekimoto G; Tahashi Y; Mori S; Uemura Y; Sakaida N; Fujisawa J; Seki T; Kobayashi K; Yokote K; Koike K; Okazaki K
Hepatology; 2009 Apr; 49(4):1203-17. PubMed ID: 19263472
[TBL] [Abstract][Full Text] [Related]
4. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma.
Matsuzaki K; Murata M; Yoshida K; Sekimoto G; Uemura Y; Sakaida N; Kaibori M; Kamiyama Y; Nishizawa M; Fujisawa J; Okazaki K; Seki T
Hepatology; 2007 Jul; 46(1):48-57. PubMed ID: 17596875
[TBL] [Abstract][Full Text] [Related]
5. Smad phosphoisoform signals in acute and chronic liver injury: similarities and differences between epithelial and mesenchymal cells.
Matsuzaki K
Cell Tissue Res; 2012 Jan; 347(1):225-43. PubMed ID: 21626291
[TBL] [Abstract][Full Text] [Related]
6. TGF-β/Smad signaling during hepatic fibro-carcinogenesis (review).
Yoshida K; Murata M; Yamaguchi T; Matsuzaki K
Int J Oncol; 2014 Oct; 45(4):1363-71. PubMed ID: 25050845
[TBL] [Abstract][Full Text] [Related]
7. Smad Phospho-Isoforms for Hepatocellular Carcinoma Risk Assessment in Patients with Nonalcoholic Steatohepatitis.
Suwa K; Yamaguchi T; Yoshida K; Murata M; Ichimura M; Tsuneyama K; Seki T; Okazaki K
Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 31991602
[TBL] [Abstract][Full Text] [Related]
8. Linker phosphorylation of Smad3 promotes fibro-carcinogenesis in chronic viral hepatitis of hepatocellular carcinoma.
Murata M; Yoshida K; Yamaguchi T; Matsuzaki K
World J Gastroenterol; 2014 Nov; 20(41):15018-27. PubMed ID: 25386050
[TBL] [Abstract][Full Text] [Related]
9. Phospho-Smad3 signaling is predictive biomarker for hepatocellular carcinoma risk assessment in primary biliary cholangitis patients.
Nakamura N; Yoshida K; Tsuda R; Murata M; Yamaguchi T; Suwa K; Ichimura M; Tsuneyama K; Matsuzaki K; Nakano T; Hirohara J; Seki T; Okazaki K; Gershwin ME; Naganuma M
Front Biosci (Landmark Ed); 2021 Dec; 26(12):1480-1492. PubMed ID: 34994163
[TBL] [Abstract][Full Text] [Related]
10. Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection.
Deng YR; Yoshida K; Jin QL; Murata M; Yamaguchi T; Tsuneyama K; Moritoki Y; Niu JQ; Matsuzaki K; Lian ZX
Clin Exp Immunol; 2014 Apr; 176(1):102-11. PubMed ID: 24372395
[TBL] [Abstract][Full Text] [Related]
11. Clinico-Pathological Importance of TGF-β/Phospho-Smad Signaling during Human Hepatic Fibrocarcinogenesis.
Yoshida K; Matsuzaki K; Murata M; Yamaguchi T; Suwa K; Okazaki K
Cancers (Basel); 2018 Jun; 10(6):. PubMed ID: 29874844
[TBL] [Abstract][Full Text] [Related]
12. TGF-β signal shifting between tumor suppression and fibro-carcinogenesis in human chronic liver diseases.
Matsuzaki K; Seki T; Okazaki K
J Gastroenterol; 2014 Jun; 49(6):971-81. PubMed ID: 24263677
[TBL] [Abstract][Full Text] [Related]
13. Smad3 Phospho-Isoform Signaling in Nonalcoholic Steatohepatitis.
Yamaguchi T; Yoshida K; Murata M; Suwa K; Tsuneyama K; Matsuzaki K; Naganuma M
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35682957
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of c-Jun NH2-terminal kinase switches Smad3 signaling from oncogenesis to tumor- suppression in rat hepatocellular carcinoma.
Nagata H; Hatano E; Tada M; Murata M; Kitamura K; Asechi H; Narita M; Yanagida A; Tamaki N; Yagi S; Ikai I; Matsuzaki K; Uemoto S
Hepatology; 2009 Jun; 49(6):1944-53. PubMed ID: 19418558
[TBL] [Abstract][Full Text] [Related]
15. Smad phospho-isoforms direct context-dependent TGF-β signaling.
Matsuzaki K
Cytokine Growth Factor Rev; 2013 Aug; 24(4):385-99. PubMed ID: 23871609
[TBL] [Abstract][Full Text] [Related]
16. Smad2 and Smad3 phosphorylated at both linker and COOH-terminal regions transmit malignant TGF-beta signal in later stages of human colorectal cancer.
Matsuzaki K; Kitano C; Murata M; Sekimoto G; Yoshida K; Uemura Y; Seki T; Taketani S; Fujisawa J; Okazaki K
Cancer Res; 2009 Jul; 69(13):5321-30. PubMed ID: 19531654
[TBL] [Abstract][Full Text] [Related]
17. Smad3 gene C-terminal phosphorylation site mutation exacerbates CCl
Yang J; Gong Y; Xu W; Li L; Shi Z; Wang Q; He Y; Zhang C; Luo C; Fang Z; Yang Y
Naunyn Schmiedebergs Arch Pharmacol; 2021 Aug; 394(8):1779-1786. PubMed ID: 34191114
[TBL] [Abstract][Full Text] [Related]
18. Smad3 phospho-isoform signaling in hepatitis C virus-related chronic liver diseases.
Yamaguchi T; Yoshida K; Murata M; Matsuzaki K
World J Gastroenterol; 2014 Sep; 20(35):12381-90. PubMed ID: 25253939
[TBL] [Abstract][Full Text] [Related]
19. Mucin1 shifts Smad3 signaling from the tumor-suppressive pSmad3C/p21(WAF1) pathway to the oncogenic pSmad3L/c-Myc pathway by activating JNK in human hepatocellular carcinoma cells.
Li Q; Liu G; Yuan H; Wang J; Guo Y; Chen T; Zhai R; Shao D; Ni W; Tai G
Oncotarget; 2015 Feb; 6(6):4253-65. PubMed ID: 25714018
[TBL] [Abstract][Full Text] [Related]
20. Modulation of TGF-beta signaling during progression of chronic liver diseases.
Matsuzaki K
Front Biosci (Landmark Ed); 2009 Jan; 14(8):2923-34. PubMed ID: 19273245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
